Trials / Terminated
TerminatedNCT00255333
INNO-105 in Patients With Solid Tumors
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Innovive Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The safety, tolerability and pharmacokinetics of INNO-105, an investigational anticancer drug, are being studied in patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INNO-105 |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-03-01
- First posted
- 2005-11-18
- Last updated
- 2007-05-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00255333. Inclusion in this directory is not an endorsement.